These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24716604)
1. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. Perron T; Emara M; Ahmed S BMC Health Serv Res; 2014 Apr; 14():162. PubMed ID: 24716604 [TBL] [Abstract][Full Text] [Related]
2. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia. Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726 [TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia. Johannesmeyer HJ; Seifert CF J Oncol Pharm Pract; 2019 Apr; 25(3):535-543. PubMed ID: 29207937 [TBL] [Abstract][Full Text] [Related]
4. Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: Is there room for improvement? Jansma B; Vakkalanka P; Talan DA; Negaard B; Faine BA J Oncol Pharm Pract; 2020 Sep; 26(6):1382-1389. PubMed ID: 31955667 [TBL] [Abstract][Full Text] [Related]
5. Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department. Peyrony O; Gerlier C; Barla I; Ellouze S; Legay L; Azoulay E; Chevret S; Fontaine JP PLoS One; 2020; 15(2):e0229828. PubMed ID: 32109264 [TBL] [Abstract][Full Text] [Related]
6. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Stern A; Carrara E; Bitterman R; Yahav D; Leibovici L; Paul M Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012184. PubMed ID: 30605229 [TBL] [Abstract][Full Text] [Related]
7. Factors associated with hospital length of stay among cancer patients with febrile neutropenia. Rosa RG; Goldani LZ PLoS One; 2014; 9(10):e108969. PubMed ID: 25285790 [TBL] [Abstract][Full Text] [Related]
8. A comparison of ED and direct admission care of cancer patients with febrile neutropenia. Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844 [TBL] [Abstract][Full Text] [Related]
9. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center. Nguyen M; Jacobson T; Torres J; Wann A Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593 [TBL] [Abstract][Full Text] [Related]
10. Emergency Ambulatory Management of Low-Risk Febrile Neutropenia: Multinational Association for Supportive Care in Cancer Fits-Real-World Experience From a UK Cancer Center. Marshall W; Campbell G; Knight T; Al-Sayed T; Cooksley T J Emerg Med; 2020 Mar; 58(3):444-448. PubMed ID: 31744709 [TBL] [Abstract][Full Text] [Related]
11. Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia. Haiduc M; Patel M; Walsh TL; Moffa MA; Bremmer DN J Oncol Pharm Pract; 2021 Mar; 27(2):297-304. PubMed ID: 32316878 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Ahn S; Rice TW; Yeung SJ; Cooksley T Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032 [TBL] [Abstract][Full Text] [Related]
13. Determination of the relationship between mortality and SOFA, qSOFA, MASCC scores in febrile neutropenic patients monitored in the intensive care unit. Cetintepe T; Cetintepe L; Solmaz S; Calık S; Ugur MC; Gediz F; Bilgir O Support Care Cancer; 2021 Jul; 29(7):4089-4094. PubMed ID: 33404806 [TBL] [Abstract][Full Text] [Related]
14. Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia. Walker ST; Grigg S; Kirkpatrick C; Urbancic K; Cohen E; Grigg A; Trubiano J Support Care Cancer; 2020 Sep; 28(9):4337-4343. PubMed ID: 31912358 [TBL] [Abstract][Full Text] [Related]
15. Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia. Loeffen EA; Te Poele EM; Tissing WJ; Boezen HM; de Bont ES Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008382. PubMed ID: 26899263 [TBL] [Abstract][Full Text] [Related]
16. Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia. Butts AR; Bachmeier CC; Dressler EV; Liu M; Cowden A; Talbert J; Adams VR J Oncol Pharm Pract; 2017 Jun; 23(4):278-283. PubMed ID: 28077045 [TBL] [Abstract][Full Text] [Related]
17. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study. Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055 [TBL] [Abstract][Full Text] [Related]
18. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Combariza JF; Lombana M; Pino LE; Arango M Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848 [TBL] [Abstract][Full Text] [Related]
19. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care. Pettit N; Boadu D; Bischof JJ Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732 [TBL] [Abstract][Full Text] [Related]
20. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]